高级别前列腺癌治疗前MRI与PSMA PET的预后增量价值有限
这项单中心回顾性研究纳入101例无远处器官转移的Gleason分级组≥3前列腺癌患者,评估治疗前mpMRI和18F-匹氟噻嗪PET/CT对无进展生存期的独立预测价值。结果显示在临床变量基础上加入影像学特征未能改善模型判别力,PI-RADS 5与较差PFS的关联为探索性发现。
要点
- 常规定量MRI和PSMA PET强度指标未能在临床变量之外独立预测PFS或改善判别力。
- 该结果提示是未能检出增量价值而非证实其不存在,影像定量指标不宜常规用于预后分层。
核心结论
- 治疗前常规定量MRI和PSMA PET强度指标在Gleason分级组≥3前列腺癌中未能在临床变量之外独立预测PFS或改善判别力。
- PI-RADS 5与较差PFS的独立关联估计不精确,仅具有假设生成意义。
研究设计与样本
- 单中心回顾性队列研究,纳入2022年活检证实的Gleason分级组≥3前列腺腺癌患者。
- 患者接受mpMRI后90天内行18F-匹氟噻嗪PET/CT检查,随访至2026年3月。
- 主要分析纳入101例无远处器官转移患者,全队列127例作为二次分析。
- 采用嵌套Cox模型比较临床变量与加入MRI和PSMA PET变量后的模型表现,以C指数和似然比检验评价。
关键影像表现/征象
- 单变量分析中较低的肿瘤最小ADC和平均ADC与进展相关(P=0.026和0.029)。
- PI-RADS 5在预设简化多变量模型中与更差PFS独立相关。
诊断标准与关键数值
- PRIMARY评分5与1–4相比与PFS无关联:HR 1.09,95%CI 0.45–2.60,P=0.852。
- 经乐观校正的C指数:仅临床变量0.77,临床加影像0.73。
临床应用与阅片要点
- PI-RADS 5虽与预后相关但估计不精确,报告时应注明其对预后分层的参考价值有限。
- ADC值和PSMA PET强度指标不应单独用于临床预后判断,需结合临床变量综合评估。
- 该研究的阴性结果提示不应因影像指标而改变基于临床变量的治疗决策。
局限性
- 单中心回顾性设计,样本量有限。
- 事件数有限,未能检出增量价值不等于证实其不存在。
- PI-RADS 5关联估计不精确,仅具假设生成意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Multiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) PET are increasingly used for pretreatment staging of prostate cancer, but their incremental prognostic value for progression-free survival (PFS) beyond clinical variables remains uncertain.
OBJECTIVE: To evaluate whether mpMRI and PSMA PET features independently predict PFS in grade group 3 or higher prostate cancer and add value beyond clinical variables.
METHODS: This single-center retrospective study included patients with biopsy-proven grade group 3 or higher prostate adenocarcinoma who underwent mpMRI followed by 18F-piflufolastat PET/CT within 90 days in 2022, with follow-up through March 2026. The primary analysis comprised 101 patients without distant organ metastasis; the full cohort of 127 patients served as a secondary analysis. Clinical, MRI, and PSMA PET variables were evaluated in nested Cox models compared by C-index and likelihood ratio tests.
RESULTS: In the primary cohort, 22 of 101 patients (22%) progressed (median follow-up, 3.2 years). Univariably, lower minimum and mean tumor ADC were associated with progression (P = 0.026 and 0.029). In the predefined reduced multivariable model, PI-RADS 5 retained an independent association with worse PFS (HR 5.69, 95% CI 1.13 to 28.65; P = .035; Firth HR 4.44, P = .026), whereas normalized ADC and intensity-based PSMA PET metrics did not. Adding imaging to clinical variables improved neither model fit (likelihood ratio P = .457) nor discrimination (optimism-corrected C-index, 0.77 clinical-only versus 0.73 clinical-plus-imaging). PRIMARY 5 versus 1-4 was not associated with PFS (HR 1.09, 0.45 to 2.60; P = 0.852).
CONCLUSION: Routine quantitative MRI and PSMA PET intensity metrics did not independently predict PFS or improve discrimination beyond clinical variables in grade group 3 or higher prostate cancer. Given the event count, this is a failure to detect incremental value rather than evidence of its absence. The PI-RADS 5 association was imprecisely estimated and is hypothesis-generating.
引用
- Aleenajitpong, Cochran, Mercaldo, et al. Limited incremental prognostic value of pretreatment MRI and 18F-piflufolastat PET intensity metrics in grade group ≥ 3 prostate cancer. Abdom Radiol (NY). 2026. PMID: 42747479. doi:10.1007/s00261-026-05796-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。